News

COVID-19 and AI: An editorial review in EMBO from Michael B. Schultz, Daniel Vera, David A. Sinclair

In early January, responding to the escalating global health crisis, BenevolentAI experts deployed our technology to identify approved drugs that could be used to treat COVID-19. Using our AI tools and biomedical knowledge graph, the team uncovered baricitinib, an approved rheumatoid arthritis drug owned by Eli Lilly, as a potential treatment.


This discovery was made by exploring ways to inhibit the cellular processes that the virus uses to infect human cells. The aim was to identify existing medicines that could potentially stop the progression of COVID-19, inhibit the “cytokine storm” and reduce the inflammatory damage associated with this disease. The team hypothesised that baricitinib may also have antiviral properties, based on its predicted ability to inhibit two members of Numb-associated kinase (NAK) family, AAK1 and GAK.

The team believes that by blocking the virus and reducing inflammation in advanced-stage patients can help to save lives, as it is the severe inflammation that causes death meaning lungs fill with fluid and patients can no longer breathe.

In a recent publication in EMBO Molecular Medicine a team of international scientists from BenevolentAI, Eli Lilly, Karolinska and clinicians in Milan validate this artificial intelligence‐assisted prediction. Using liver organoids infected with SARS‐CoV‐2, they confirm dual antiviral and anti‐inflammatory activities. They also show disease improvement in four COVID‐19 patients who were given baricitinib, paving the way for more rigorous placebo‐controlled trials.

In this editorial comment, Michael B. Schultz, Daniel Vera and David Sinclair review these findings and explore the broader, longer-term implications of the AI-powered study on drug discovery: “Here, the marriage of machine learning and rapid clinical trials provides hope for progress, not only in today’s fight against COVID-19, but in the ongoing fight against acute and chronic diseases”.

Access the review in EMBO Molecular Medicine:

PUBLICATION


More Posts

You Might Also Like

Video
Data & Digital Innovation for Climate & Health
Joanna Shields, CEO BenevolentAI, joined the Wellcome Trust Panel at the World Economic forum to discuss opportunities for data and digital innovation to impact positively climate and health.
Jan 26, 2023
News
BenevolentAI submits CTA for BEN-8744, an oral PDE10 inhibitor, as a first-in-class treatment for ulcerative colitis
BenevolentAI submits clinical trial application for BEN-8744, with a Phase I clinical trial planned for H1 2023.
Dec 21, 2022
News
BenevolentAI to present at 41st Annual J.P. Morgan Healthcare Conference
BenevolentAI ​​(Euronext Amsterdam: BAI), a leading clinical-stage AI drug discovery company, announces that it will participate in the upcoming 41st Annual J.P. Morgan Healthcare Conference in San Francisco, US from 9-12 January 2023.
Dec 1, 2022
Blog
FAIR Data Foundation: An Enabler for AI Drug Discovery
Biomedical data used in AI-enabled drug discovery should adhere to the FAIR Data Principles — Findability, Accessibility, Interoperability and Reusability. This blog explains why this is, how one can make data FAIR and challenges that remain.
Nov 8, 2022
News
BenevolentAI to present at Jefferies Investor Conference in November
BenevolentAI’s Investor Relations and Business Development team will be attending the Jefferies Healthcare London conference, with Nick Keher, CFO, presenting on Thursday 17th November.
Nov 4, 2022
News
BenevolentAI achieves further milestones in AI-enabled target identification collaboration with AstraZeneca
Two additional AI-generated novel targets selected by AstraZeneca for its drug development portfolio, resulting in two milestone payments for BenevolentAI.
Oct 6, 2022